Who is the CEO of Novartis?
Vasant Narasimhan (Feb 1, 2018–)Novartis / CEOVasant “Vas” Narasimhan is an Indian-American physician and the chief executive officer of Novartis. Wikipedia
How long does it take to get hired at Novartis?
It took up to two months. It depends on the position, I would say 2-3 weeks.
Is Sandoz part of Novartis?
Sandoz is a division of the Novartis Group and a global leader in generic pharmaceuticals and biosimilars. The division was established in 2003, when Novartis united all of its generics businesses under the name Sandoz – a single global brand with a long history.
What is Novartis CEO salary?
What is the salary of Vasant Narasimhan? As the Chief Executive Officer and Member of the Executive Committee of Novartis AG, the total compensation of Vasant Narasimhan at Novartis AG is $11,437,500.
How much does the Novartis CEO make?
Novartis’ group sales took a hit from COVID-19, and so did CEO Vas Narasimhan’s 2020 pay. The Swiss pharma handed its CEO a pay package worth CHF10. 38 million ($11.61 million) for 2020, down from CHF 11.44 million in 2019, according to its annual report (PDF).
How can I contact Novartis for product information?
For product-related inquiries and medical information about our products, please contact the Novartis office in your country.
What is Novartis doing for You?
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis is building an Inspired, Curious and Unbossed culture. Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.
What is the Novartis Information Center?
The information center provides a central hub for news, guidance and resources. Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis is building an Inspired, Curious and Unbossed culture.
What is new at Novartis in 2019?
Oct 22, 2019. Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US. Oct 16, 2019. Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease.